Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.

Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD.

Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018.

2.

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy.

Raj S, Miller LD, Triozzi PL.

Sarcoma. 2018 Aug 12;2018:9305294. doi: 10.1155/2018/9305294. eCollection 2018. Review.

3.

Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.

Neuroradiology. 2018 Oct;60(10):1043-1051. doi: 10.1007/s00234-018-2060-y. Epub 2018 Aug 10.

PMID:
30094640
4.

CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools.

Chmielewski JP, Bowlby SC, Wheeler FB, Shi L, Sui G, Davis AL, Howard TD, D'Agostino RB Jr, Miller LD, Sirintrapun SJ, Cramer SD, Kridel SJ.

Mol Cancer Res. 2018 Nov;16(11):1687-1700. doi: 10.1158/1541-7786.MCR-17-0526. Epub 2018 Aug 3.

PMID:
30076241
5.

Endovascular Repair of Superior Mesenteric Arteriovenous Fistula Causing Early Mesenteric Steal Syndrome Following Abdominal Gunshot Injury.

Miller LD, Hilliard NJ, Harper SJF.

EJVES Short Rep. 2018 Jun 5;39:58-60. doi: 10.1016/j.ejvssr.2018.05.007. eCollection 2018.

6.

Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer.

Panigrahi GK, Ramteke A, Birks D, Abouzeid Ali HE, Venkataraman S, Agarwal C, Vibhakar R, Miller LD, Agarwal R, Abd Elmageed ZY, Deep G.

Oncotarget. 2018 Feb 17;9(17):13894-13910. doi: 10.18632/oncotarget.24532. eCollection 2018 Mar 2.

7.

A collection of annotated and harmonized human breast cancer transcriptome datasets, including immunologic classification.

Roelands J, Decock J, Boughorbel S, Rinchai D, Maccalli C, Ceccarelli M, Black M, Print C, Chou J, Presnell S, Quinn C, Jithesh P, Syed N, Al Bader SBJ, Bedri S, Wang E, Marincola FM, Chaussabel D, Kuppen P, Miller LD, Bedognetti D, Hendrickx W.

Version 2. F1000Res. 2017 Mar 20 [revised 2018 Jan 1];6:296. doi: 10.12688/f1000research.10960.2. eCollection 2017.

8.

A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.

Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd DD, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2018 May 1;24(9):2060-2073. doi: 10.1158/1078-0432.CCR-17-2282. Epub 2018 Feb 6.

PMID:
29437791
9.

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.

Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A.

Oncologist. 2018 Apr;23(4):481-488. doi: 10.1634/theoncologist.2017-0398. Epub 2018 Jan 12.

PMID:
29330212
10.

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?

Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, Miller LD, Hawkins GA, Grant SC, DeYoung BR, Petty WJ, Chen K, Pasche BC, Zhang W.

Ann Oncol. 2018 Feb 1;29(2):311-323. doi: 10.1093/annonc/mdx766.

PMID:
29216340
11.

Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center.

Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC, Petty WJ, Alistar AT, Levine EA, Staren ED, Langefeld CD, Miller V, Singal G, Petro RM, Robinson M, Blackstock W, Powell BL, Wagner LI, Foley KL, Abraham E, Pasche B, Zhang W.

Theranostics. 2017 Jul 12;7(11):2914-2923. doi: 10.7150/thno.20355. eCollection 2017.

12.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.

J Immunother Cancer. 2017 May 16;5:44. doi: 10.1186/s40425-017-0243-4. eCollection 2017. Review.

13.

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.

Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV.

Breast Cancer Res. 2017 Mar 28;19(1):42. doi: 10.1186/s13058-017-0830-9. No abstract available.

14.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.

Oncoimmunology. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. eCollection 2017.

15.

Iron addiction: a novel therapeutic target in ovarian cancer.

Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller LD, Dyment N, Torti FM, Torti SV.

Oncogene. 2017 Jul 20;36(29):4089-4099. doi: 10.1038/onc.2017.11. Epub 2017 Mar 20.

16.

Conservation of immune gene signatures in solid tumors and prognostic implications.

Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD.

BMC Cancer. 2016 Nov 22;16(1):911.

17.

APOL1 Renal-Risk Variants Induce Mitochondrial Dysfunction.

Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI.

J Am Soc Nephrol. 2017 Apr;28(4):1093-1105. doi: 10.1681/ASN.2016050567. Epub 2016 Nov 7.

18.

Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.

Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG.

Clin Breast Cancer. 2017 Apr;17(2):139-153. doi: 10.1016/j.clbc.2016.09.001. Epub 2016 Sep 13.

19.

Treating child and adolescent anxiety effectively: Overview of systematic reviews.

Bennett K, Manassis K, Duda S, Bagnell A, Bernstein GA, Garland EJ, Miller LD, Newton A, Thabane L, Wilansky P.

Clin Psychol Rev. 2016 Dec;50:80-94. doi: 10.1016/j.cpr.2016.09.006. Epub 2016 Sep 21. Review.

PMID:
27744168
20.

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.

Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.

Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28.

21.

Effects of Pubertal Exposure to Dietary Soy on Estrogen Receptor Activity in the Breast of Cynomolgus Macaques.

Dewi FN, Wood CE, Willson CJ, Register TC, Lees CJ, Howard TD, Huang Z, Murphy SK, Tooze JA, Chou JW, Miller LD, Cline JM.

Cancer Prev Res (Phila). 2016 May;9(5):385-95. doi: 10.1158/1940-6207.CAPR-15-0165. Epub 2016 Mar 22.

22.

Disentangling the relationship between tumor genetic programs and immune responsiveness.

Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.

Curr Opin Immunol. 2016 Apr;39:150-8. doi: 10.1016/j.coi.2016.02.001. Epub 2016 Mar 9. Review.

PMID:
26967649
23.

Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix.

Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.

J Am Coll Surg. 2016 Apr;222(4):493-503. doi: 10.1016/j.jamcollsurg.2015.12.012. Epub 2015 Dec 21.

24.

Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation.

Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G.

J Mol Cell Biol. 2016 Jun;8(3):232-43. doi: 10.1093/jmcb/mjw002. Epub 2016 Jan 13.

25.

ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer.

Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjöld B, Yu JJ, Stål O, Holz MK.

Clin Cancer Res. 2016 Mar 15;22(6):1421-31. doi: 10.1158/1078-0432.CCR-15-0857. Epub 2015 Nov 5.

26.

Prognostic and predictive immune gene signatures in breast cancer.

Bedognetti D, Hendrickx W, Marincola FM, Miller LD.

Curr Opin Oncol. 2015 Nov;27(6):433-44. doi: 10.1097/CCO.0000000000000234. Review.

PMID:
26418235
27.

PREVENTING CHILD AND ADOLESCENT ANXIETY DISORDERS: OVERVIEW OF SYSTEMATIC REVIEWS.

Bennett K, Manassis K, Duda S, Bagnell A, Bernstein GA, Garland EJ, Miller LD, Newton A, Thabane L, Wilansky P.

Depress Anxiety. 2015 Dec;32(12):909-18. doi: 10.1002/da.22400. Epub 2015 Aug 18. Review.

PMID:
26282454
28.

Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer.

Song Q, Wang H, Bao J, Pullikuth AK, Li KC, Miller LD, Zhou X.

Sci Rep. 2015 Aug 10;5:12981. doi: 10.1038/srep12981.

29.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design.

Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.

J Neurooncol. 2015 Sep;124(3):447-53. doi: 10.1007/s11060-015-1858-2. Epub 2015 Jul 18.

30.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.

Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.

Cancer Biol Ther. 2015;16(5):678-83. doi: 10.1080/15384047.2015.1026481.

31.

Hepcidin regulation in prostate and its disruption in prostate cancer.

Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.

Cancer Res. 2015 Jun 1;75(11):2254-63. doi: 10.1158/0008-5472.CAN-14-2465. Epub 2015 Apr 9.

32.

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction.

Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R Jr, Miller LD.

Genome Med. 2014 Oct 28;6(10):80. doi: 10.1186/s13073-014-0080-8. eCollection 2014.

33.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.

Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27.

34.

DEAD-box helicase DP103 defines metastatic potential of human breast cancers.

Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP, Tergaonkar V.

J Clin Invest. 2014 Sep;124(9):3807-24. doi: 10.1172/JCI73451. Epub 2014 Aug 1.

35.

The effect of a nurse-led multidisciplinary team on ventilator-associated pneumonia rates.

Dosher WB, Loomis EC, Richardson SL, Crowell JA, Waltman RD, Miller LD, Nazim M, Khasawneh FA.

Crit Care Res Pract. 2014;2014:682621. doi: 10.1155/2014/682621. Epub 2014 Jun 29.

36.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma.

Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.

J Neurooncol. 2014 Sep;119(2):429-35. doi: 10.1007/s11060-014-1515-1. Epub 2014 Jul 3.

37.

Emergency department referral for organ donation: more organ donors and more organs per donor.

Miller LD, Gardiner SK, Gubler KD.

Am J Surg. 2014 May;207(5):728-33; discussion 733-4. doi: 10.1016/j.amjsurg.2013.12.017. Epub 2014 Mar 6.

PMID:
24791635
38.

Multiple informant agreement of child, parent, and teacher ratings of child anxiety within community samples.

Miller LD, Martinez YJ, Shumka E, Baker H.

Can J Psychiatry. 2014 Jan;59(1):34-9.

39.

Identifying driver genes in cancer by triangulating gene expression, gene location, and survival data.

Rouam S, Miller LD, Karuturi RK.

Cancer Inform. 2015 Feb 3;13(Suppl 6):35-48. doi: 10.4137/CIN.S18302. eCollection 2014. Review.

40.

IRP2 regulates breast tumor growth.

Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV.

Cancer Res. 2014 Jan 15;74(2):497-507. doi: 10.1158/0008-5472.CAN-13-1224. Epub 2013 Nov 27.

41.

The regulation of SOX7 and its tumor suppressive role in breast cancer.

Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G.

Am J Pathol. 2013 Nov;183(5):1645-1653. doi: 10.1016/j.ajpath.2013.07.025. Epub 2013 Sep 5.

42.

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis.

Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD.

Genome Biol. 2013 Apr 29;14(4):R34. doi: 10.1186/gb-2013-14-4-r34.

43.

Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.

Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H.

Hepatology. 2013 Apr;57(4):1469-83. doi: 10.1002/hep.26159. Epub 2013 Mar 6.

PMID:
23175232
44.

Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer.

Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K.

Oncogene. 2013 Aug 29;32(35):4120-9. doi: 10.1038/onc.2012.423. Epub 2012 Oct 8.

45.

JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.

Lee YF, Miller LD, Chan XB, Black MA, Pang B, Ong CW, Salto-Tellez M, Liu ET, Desai KV.

Breast Cancer Res. 2012 May 23;14(3):R85. Erratum in: Breast Cancer Res. 2017 Mar 28;19(1):42.

46.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.

Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.

Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7.

47.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.

Ann Oncol. 2012 Nov;23(11):2866-73. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24.

48.

Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27.

Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G.

Am J Pathol. 2012 May;180(5):2120-33. doi: 10.1016/j.ajpath.2012.01.037. Epub 2012 Mar 20.

49.

RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally.

Miller MS, Miller LD.

Front Genet. 2012 Jan 3;2:100. doi: 10.3389/fgene.2011.00100. eCollection 2011.

50.

YB-1, the E2F pathway, and regulation of tumor cell growth.

Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW.

J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28.

Supplemental Content

Loading ...
Support Center